Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
McKesson
Federal Trade Commission
Healthtrust
Chinese Patent Office
Fuji
Moodys
Express Scripts
McKinsey
Farmers Insurance

Generated: August 18, 2017

DrugPatentWatch Database Preview

Polidocanol - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for polidocanol and what is the scope of polidocanol freedom to operate?

Polidocanol
is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has one hundred and seventy-seven patent family members in forty countries.

Two suppliers are listed for this compound.

Summary for Generic Name: polidocanol

Tradenames:2
Patents:15
Applicants:2
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list22
Clinical Trials: see list16
Patent Applications: see list1,609
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:polidocanol at DailyMed

Pharmacology for Ingredient: polidocanol

Drug ClassSclerosing Agent
Mechanism of ActionSclerosing Activity
Physiological EffectVascular Sclerosing Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemisch Fbrk Krsslr
ASCLERA
polidocanol
SOLUTION;INTRAVENOUS021201-002Mar 30, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013► Subscribe► Subscribe
Provensis
VARITHENA
polidocanol
SOLUTION;INTRAVENOUS205098-001Nov 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: polidocanol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,763,269Therapeutic foam► Subscribe
5,676,962 Injectable microfoam containing a sclerosing agent► Subscribe
8,091,801Generation of therapeutic microfoam► Subscribe
RE38919 Injectable microfoam containing a sclerosing agent► Subscribe
8,048,439Therapeutic foam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: polidocanol

Country Document Number Estimated Expiration
Portugal2759291► Subscribe
Eurasian Patent Organization200600985► Subscribe
Hong Kong1200316► Subscribe
Japan2007511590► Subscribe
European Patent Office1945533► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Accenture
Deloitte
AstraZeneca
Federal Trade Commission
Colorcon
Daiichi Sankyo
Mallinckrodt
Baxter
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot